Cargando…
Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation
Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet acti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283519/ https://www.ncbi.nlm.nih.gov/pubmed/25601838 http://dx.doi.org/10.3389/fphys.2014.00501 |
_version_ | 1782351276330188800 |
---|---|
author | Suslova, Tatiana E. Sitozhevskii, Alexei V. Ogurkova, Oksana N. Kravchenko, Elena S. Kologrivova, Irina V. Anfinogenova, Yana Karpov, Rostislav S. |
author_facet | Suslova, Tatiana E. Sitozhevskii, Alexei V. Ogurkova, Oksana N. Kravchenko, Elena S. Kologrivova, Irina V. Anfinogenova, Yana Karpov, Rostislav S. |
author_sort | Suslova, Tatiana E. |
collection | PubMed |
description | Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated. |
format | Online Article Text |
id | pubmed-4283519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42835192015-01-19 Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation Suslova, Tatiana E. Sitozhevskii, Alexei V. Ogurkova, Oksana N. Kravchenko, Elena S. Kologrivova, Irina V. Anfinogenova, Yana Karpov, Rostislav S. Front Physiol Physiology Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high risk of microcirculation complications and microangiopathies. An increase in thrombogenic risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis. Factors leading to platelet activation in MetS and T2DM comprise insulin resistance, hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity in MetS patients can play a central role in the manifestation of platelet hyperactivation. Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets. This review provides data on the insulin effects in platelets. Decrease in a number and sensitivity of the insulin receptors on platelets in T2DM can cause platelet hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review presents data suggesting an ability of platelets to synthesize humoral factors stimulating thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers of T2DM and cardiovascular complications and are involved in the development of dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated signaling pathway in the effects of cytokines on platelet aggregation. The effects of the proinflammatory cytokines on functional activity of platelets are demonstrated. Frontiers Media S.A. 2015-01-05 /pmc/articles/PMC4283519/ /pubmed/25601838 http://dx.doi.org/10.3389/fphys.2014.00501 Text en Copyright © 2015 Suslova, Sitozhevskii, Ogurkova, Kravchenko, Kologrivova, Anfinogenova and Karpov. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Suslova, Tatiana E. Sitozhevskii, Alexei V. Ogurkova, Oksana N. Kravchenko, Elena S. Kologrivova, Irina V. Anfinogenova, Yana Karpov, Rostislav S. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation |
title | Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation |
title_full | Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation |
title_fullStr | Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation |
title_full_unstemmed | Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation |
title_short | Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation |
title_sort | platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cgmp- and no-dependent mechanisms in the insulin-mediated platelet aggregation |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283519/ https://www.ncbi.nlm.nih.gov/pubmed/25601838 http://dx.doi.org/10.3389/fphys.2014.00501 |
work_keys_str_mv | AT suslovatatianae platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation AT sitozhevskiialexeiv platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation AT ogurkovaoksanan platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation AT kravchenkoelenas platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation AT kologrivovairinav platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation AT anfinogenovayana platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation AT karpovrostislavs platelethemostasisinpatientswithmetabolicsyndromeandtype2diabetesmellituscgmpandnodependentmechanismsintheinsulinmediatedplateletaggregation |